doi: 10.1016/j.aott.2018.01.002
It belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking natural hormones that regulate hunger, satiety, and energy use
Common reports include soreness at the injection site, nausea, headache, and tiredness
The abdomen absorbs insulin the fastest, followed by the arms, thighs, and buttocks
Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)
CMS Administrator Mehmet Oz, MD, expressed his support for the measure
